Propranolol Sandoz 40 mg tablete Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

propranolol sandoz 40 mg tablete

sandoz d.o.o., maksimirska 120, zagreb - propranololklorid - tableta - 40 mg - urbroj: jedna tableta sadrži 40 mg propranololklorida

Volqer 200 mg tablete s produljenim oslobađanjem Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

volqer 200 mg tablete s produljenim oslobađanjem

sandoz d.o.o., maksimirska 120, zagreb - quetiapinum - tableta s produljenim oslobađanjem - 200 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 200 mg kvetiapina (u obliku kvetiapinfumarata)

Volqer 300 mg tablete s produljenim oslobađanjem Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

volqer 300 mg tablete s produljenim oslobađanjem

sandoz d.o.o., maksimirska 120, zagreb - quetiapinum - tableta s produljenim oslobađanjem - 300 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 300 mg kvetiapina (u obliku kvetiapinfumarata)

Volqer 400 mg tablete s produljenim oslobađanjem Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

volqer 400 mg tablete s produljenim oslobađanjem

sandoz d.o.o., maksimirska 120, zagreb - quetiapinum - tableta s produljenim oslobađanjem - 400 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 400 mg kvetiapina (u obliku kvetiapinfumarata)

Volqer 50 mg tablete s produljenim oslobađanjem Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

volqer 50 mg tablete s produljenim oslobađanjem

sandoz d.o.o., maksimirska 120, zagreb - quetiapinum - tableta s produljenim oslobađanjem - 50 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 50 mg kvetiapina (u obliku kvetiapinfumarata)

Rivaroxaban Accord Unió Europea - croat - EMA (European Medicines Agency)

rivaroxaban accord

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Unió Europea - croat - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Vixargio 2,5 mg filmom obložene tablete Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

vixargio 2,5 mg filmom obložene tablete

viatris limited, damastown industrial park, mulhuddart, dublin, irska - rivaroksaban - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 2,5 mg rivaroksabana

Xaboplax 2,5 mg filmom obložene tablete Croàcia - croat - HALMED (Agencija za lijekove i medicinske proizvode)

xaboplax 2,5 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - rivaroksaban - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 2,5 mg rivaroksabana

Adcirca (previously Tadalafil Lilly) Unió Europea - croat - EMA (European Medicines Agency)

adcirca (previously tadalafil lilly)

eli lilly nederland b.v. - tadalafil - hipertenzija, plućna - urologicals - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. učinkovitost je pokazana u idiopatskom pah (ipah) i pah povezanoj na vaskularnu bolest kolagena. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.